Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Gold in the ivory tower: equity rewards of outlicensing

Nature Biotechnology volume 24, pages 509–515 (2006)Cite this article

An analysis of life-science initial public offerings from three time periods reveals that the equity share received by universities and their academic researchers has changed over time.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Capital invested in biotech companies.
Figure 2: Valuation step-ups by investment round.
Figure 3: Aggregate technology value of biotech companies.
Figure 4
Figure 5
Figure 6: Typical university-biotech license terms.

References

  1. Edwards, M., Murray, F. & Yu, R. Nat. Biotechnol. 21, 618–624 (2003).

    Article  CAS  Google Scholar 

  2. AUTM licensing survey, fiscal year 2003 (The Association of University Technology Managers, Inc., Northbrook, Illinois, 2000).

  3. Kenney, M. Biotechnology: The University Industrial Complex. (Yale University Press, New Haven, Connecticut, 1986).

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. managing director, Recombinant Capital, 2033 North Main Street, Walnut Creek, 94596, California, USA

    Mark Edwards

  2. analyst at Recombinant Capital, 2033 North Main Street, Walnut Creek, 94596, California, USA

    Robert Yu

  3. MIT Sloan School of Management and the Harvard-MIT Division of Health Sciences & Technology, 50 Memorial Drive E52-567, Cambridge, 02142, Massachusetts, USA

    Fiona Murray

Authors
  1. Mark Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fiona Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edwards, M., Murray, F. & Yu, R. Gold in the ivory tower: equity rewards of outlicensing. Nat Biotechnol 24, 509–515 (2006). https://doi.org/10.1038/nbt0506-509

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0506-509

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing